JSS Stock Overview
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Nxera Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥8.80 |
| 52 Week High | JP¥20.60 |
| 52 Week Low | JP¥8.00 |
| Beta | 0.57 |
| 1 Month Change | -8.33% |
| 3 Month Change | 1.15% |
| 1 Year Change | -48.84% |
| 3 Year Change | -31.78% |
| 5 Year Change | -22.83% |
| Change since IPO | 8.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| JSS | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.2% | 3.2% | 1.7% |
| 1Y | -48.8% | -28.2% | 2.3% |
Price Volatility
| JSS volatility | |
|---|---|
| JSS Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: JSS's share price has been volatile over the past 3 months.
Volatility Over Time: JSS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 350 | Chris Cargill | soseiheptares.com |
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.
Nxera Pharma Co., Ltd. Fundamentals Summary
| JSS fundamental statistics | |
|---|---|
| Market cap | €800.96m |
| Earnings (TTM) | -€43.08m |
| Revenue (TTM) | €76.46m |
10.5x
P/S Ratio-18.6x
P/E RatioIs JSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JSS income statement (TTM) | |
|---|---|
| Revenue | JP¥12.77b |
| Cost of Revenue | JP¥3.10b |
| Gross Profit | JP¥9.66b |
| Other Expenses | JP¥16.86b |
| Earnings | -JP¥7.19b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -80.42 |
| Gross Margin | 75.70% |
| Net Profit Margin | -56.35% |
| Debt/Equity Ratio | 103.5% |
How did JSS perform over the long term?
See historical performance and comparison